Significant hyponatremia following DDAVP administration in a healthy adult.
We report the development of significant hyponatremia (121 mEq/L) following three daily intravenous doses of desmopressin acetate (DDAVP; 18 micrograms; 0.3 micrograms/kg) in a healthy adult with moderate von Willebrand's disease. Previous reports suggest that clinically important hyponatremia due to DDAVP administration only occurs in the very young, those receiving hypotonic intravenous fluids or those given multiple frequent (e.g., every 8-12 hours) doses of DDAVP. None of these conditions was present in this case. Consideration should be given to monitoring serum sodium levels and fluid balance in patients receiving more than a single dose of DDAVP, even in the absence of previously reported risk factors for the development of hyponatremia.
Humphries
J E
JE
Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville.
Siragy
H
H
D000328:Adult; D000367:Age Factors; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced* / Q000453:epidemiology / Q000209:etiology; D007275:Injections, Intravenous; D012307:Risk Factors; D012964:Sodium / Q000032:analysis; D014882:Water-Electrolyte Balance; D014842:von Willebrand Diseases / Q000188:drug therapy
D012964:Sodium; D003894:Deamino Arginine Vasopressin